The three-year deal covers incorporating antibodies to 10 cancer targets into a HPK1- (hematopoietic progenitor kinase 1) inhibited CAR T-cell platform. HPK1 promotes T-cell exhaustion, which is a strategy that can be used to improve CAR T-cell immunotherapy.

Seattle Genetics, Merck partner on 2 oncology drug programs
Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately,...

Neogene Therapeutics to develop personalized cell therapies
Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series...

New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that...

Integral Molecular aids with safety testing of COVID-19 antibodies
Integral Molecular is applying its membrane proteome array technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic...